
    
      This is an observational study conducted in patients with type 2 diabetes starting treatment
      with either GLP-1 receptor agonist or sodium-glucose cotransporter-2 (SGLT-2) inhibitor.

      Planned study cohort consists of 60 patients: 30 patients starting GLP-1 receptor agonist
      treatment and 30 patients starting SGLT-2 inhibitor treatment. All patients must have
      metformin as background therapy. All other diabetes medications are allowed.

      Patients are tested before starting treatment, at 1 month (stool sample only), 3 months and
      12 months after starting treatment. The primary endpoint is change in overnight urinary
      aldosterone corrected for creatinine.

      Secondary endpoint is change in intestinal microbiota composition.
    
  